Page 43 - CIBERDEM2016-ENG

Most relevant scientific articles
• Elias I., Ferre T., Vila L., Munoz S., Casellas A., García M. et al. ALOX5AP overexpression in adipose tissue leads to LXA4 production and protection against diet-induced obesity and insulin resistance. Diabetes. 2016;65(8):2139-2150.
• Motas S, Haurigot V, Garcia M, Marcó S, Ribera A, Roca C et al. CnS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI insight. 2016;1(9): e86696.
• Vilà L, Roca C, Elias I, Casellas A, Lage R, Franckhauser S et al. AAV-mediated Sirt1 overexpression in skeletal muscle activates oxidative capacity but does not prevent insulin resistance. Molecular therapy. Methods & clinical development. 2016;5:16072.
• Albert V, Svensson K, Shimobayashi M, Colombi M, Muñoz S, Jiménez V et al. mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue. EMBO molecular medicine. 2016;.
• Lagarrigue S., López-Mejia I.C., Denechaud P.-D., Escote X., Castillo-Armengol J., Jiménez V. et al. CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation. 2016;126(1):335-348.
Highlights
In 2016, the second part of a project funded by the Juvenile Diabetes Research Foundation have been implemented: “BetaSel2 - Therapeutic efficacy of novel cytokines and growth factors selected to improve beta cell mass vivo”, in order to identify candidates to counteract type 1 diabetes. We have also obtained interesting results in the framework of the project funded by the Ministry of education and competitiveness (SAF2014-54866-R), “New approaches to gene therapy for type 2 diabetes and obesity based on the activation of brown adipose tissue and browning of white adipose tissue”. In addition, we have initiated a project funded by the EU, “Development of an innovative gene therapy platform for rare hereditary muscle disorders (MYOCURE)” to develop new approaches of gene therapy for rare muscular diseases, whose results will be of potential interest for the development of new strategies for the treatment of diabetes.
On the other hand, we participate in international initiatives such as the EU, “European infrastructure
for phenotyping and archiving of model mammalian genomes (Infrafrontier-I3)” and the “Research Infrastructure for Phenotyping, Archiving and Distribution of Mouse Disease Models (IPAD-MD)”, or the Consortium “International Mouse Phenotyping Consortium (IMPC)” aiming at phenotyping, archiving
and distributing mouse models to the scientific community. We also participate in the EU COST action “Development of a European network for preclinical testing of interventions in mouse models of age and age-related diseases (MouseAGE)”, in order to study aging in mice, and the EU COST action “European Network of Multidisciplinary Research and Translation of Autophaghy knowledge (TRANSAUTOPHAGHY)” to study the regulation of Autophagy.
Within the framework of the public / private partnership signed between UAB and Esteve, we are developing gene therapy approaches towards the clinic for rare inherited metabolic disorders (Mucopolysaccharidosis). In this field, we are also participating in the project “AAV-mediated gene therapy for the treatment of MPSIIID (Sanfilippo D)” financed by Association Française contre les Myopathies.
DEM
research groups 43